Ships from British Columbia, Canada|Canadian Orders Ship Domestically, No Border Crossing|International Shipping Available|Lab Verified|≥98% Purity Guarantee|Shipped Within 24hr|Batch-Specific COAs|Ships from British Columbia, Canada|Canadian Orders Ship Domestically, No Border Crossing|International Shipping Available|Lab Verified|≥98% Purity Guarantee|Shipped Within 24hr|Batch-Specific COAs|Ships from British Columbia, Canada|Canadian Orders Ship Domestically, No Border Crossing|International Shipping Available|Lab Verified|≥98% Purity Guarantee|Shipped Within 24hr|Batch-Specific COAs|Ships from British Columbia, Canada|Canadian Orders Ship Domestically, No Border Crossing|International Shipping Available|Lab Verified|≥98% Purity Guarantee|Shipped Within 24hr|Batch-Specific COAs|
All Comparisons

IGF-1 LR3 vs MGF

Research material comparison: purity standards, available formats, molecular data, batch COA documentation, and regulatory status. For in vitro research use only.

IGF-1 LR3: DMGF: D
AttributeIGF-1 LR3MGF
CategoryGrowth FactorGrowth Factor
Evidence RatingDPreclinicalDPreclinical
Clinical StatusNo clinical trials for therapeutic use. Research compound only.Preclinical only. No human clinical trials.
MechanismIGF-1 LR3 binds to IGF-1 receptors on target cells with high affinity, initiating tyrosine kinase signaling that activates the PI3K/Akt/mTOR pathway, increasing protein synthesis, glucose uptake, and cellular survival while inhibiting muscle protein breakdown (anti-catabolic). Its low affinity for I...MGF is expressed as part of the IGF-1 gene through alternative splicing in response to mechanical overload or tissue damage. The E-domain peptide (distinct from the mature IGF-1 peptide) activates satellite cells — muscle stem cells that donate nuclei to growing or repairing muscle fibers. It upregu...
Half-Life20-30 hoursMinutes (non-PEGylated); rapidly degraded by serum proteases
Bioavailability
Molecular Weight~9,111 g/mol (9.1 kDa)
WADA StatusProhibitedProhibited
Research Half-Life20-30 hoursMinutes (non-PEGylated); rapidly degraded by serum proteases
Key Use Cases
  • Body Composition
  • Injury Recovery
  • Muscle Research
Safety Concerns
  • Hypoglycemia risk — IGF-1 has insulin-like glucose-lowering effects
  • Potential organ enlargement with chronic use (intestinal growth observed in animals)
  • Joint pain, water retention, carpal tunnel-like symptoms (GH/IGF axis effects)
  • No human safety data exists
  • Theoretical risks include uncontrolled cell proliferation
  • Extremely short half-life of the non-PEGylated form may limit both efficacy and toxicity
Contraindications
  • Active cancer or history of cancer (IGF-1 promotes cell proliferation)
  • Diabetes or hypoglycemia disorders
  • Pregnancy and breastfeeding
  • Under 25 years old (growth plate closure concerns)
  • Active cancer or history of cancer (growth factor concern)
  • Pregnancy and breastfeeding (no safety data)
Regulatory (US)Not FDA-approved. Research chemical only. WADA-banned (S2 growth factors).Not FDA-approved. Research chemical only. WADA-banned.

Research Material Specifications

Catalog specifications for the corresponding research materials, including batch documentation coverage.

SpecificationIGF-1 LR3MGF
Purity Standard≥98%≥98%
CAS NumberN/AN/A
Molecular FormulaN/AN/A
Available Formats1mg2mg
Batch COAs Published
Stock StatusOut of stockOut of stock

Research Disclaimer: This comparison is provided for educational purposes only. All products are sold exclusively for in vitro research use. The information presented is based on published preclinical and clinical research and does not constitute medical advice. Consult a qualified healthcare professional before making any decisions regarding peptide use.

Explore More
Comparisons

Compare any two peptides side-by-side or browse our curated popular matchups.

Your Cart

Your cart is empty

Browse our catalog to add research compounds.